SEC Tracker
Get the app
IVF · XBRL financial data

INVO Fertility financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (IVF's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue—year only1,5761,8371,4331,686*1,6371,8641,7571,583*2,0152,175
Revenue from contracts with customers9751,382*1,5761,8371,4331,715*1,642—————
Cost of revenue581925*8508629881,017*1,064—————
Cost of goods and services sold—————year only43—year only560
Research and development36*50*0*485*266—————
Selling, general and administrative1,2571,856*1,4412,6481,5153,476*2,5542,1932,1281,813*2,1761,907
General and administrative—year only272——year only1,308—————
Total operating expenses1,8612,890*———year only——————
Operating income (loss)(886)(1,508)*(946)(1,903)(1,300)(3,976)*(17,107)(2,990)(1,635)(1,412)*(1,591)(1,290)
Interest expense352182*181370274232*(311)221146627*180177
Income tax expense (benefit)223*20*29(54)*0——year only056
Net income (loss)(1,248)(1,995)*(1,597)(2,245)(1,631)(3,623)*(17,404)(5,285)(2,645)2,010*(5,539)889
Earnings per share, basic USD per share(0.70)—(0.42)(0.62)(0.42)—(12.53)(13.30)(0.77)—(3.38)0.42
Earnings per share, diluted USD per share(0.70)—(0.42)(0.62)(0.42)—(12.53)(13.30)(0.77)—(3.38)0.35
Weighted average shares, basic thousands of shares1,777—3,8023,6103,886—1,3893973,448—1,6382,106
Weighted average shares, diluted thousands of shares1,777—3,8023,6103,886—1,3893973,448—1,6382,592
  • † Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (IVF's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1,0562324759434727418405493562,0784,9043,733
Accounts receivable117141177257257175174242274217248258
Inventory254265266250242220216213192225225251
Prepaid and other current assets365622806946987182339395315241357361
Total current assets1,7921,2601,7252,3961,9571,3181,5691,3991,1372,7625,7344,603
Property and equipment, net772826412441415467451429405386475833
Right-of-use asset5,8583,3593,3692,3372,3442,2842,2232,1602,0971,2861,9762,152
Goodwill8,2255,8795,8795,8795,87923,5368,8915,8795,8795,8796,5199,252
Total assets19,47618,50618,31817,75517,01946,44931,74419,31918,83220,22024,65625,835
Current portion of long-term debt—————6,338—3,7691,0291,2751,2431,127
Total current liabilities4,8848,0038,9567,9528,65517,92618,71912,4639,24510,3326,3566,520
Long-term debt—————1,129—1,041952745660513
Lease liability, non-current5,6223,3563,1382,2662,2532,1902,1252,0581,9871,1711,8111,874
Total liabilities19,10317,61318,30816,39117,04326,24524,43016,68812,98312,9969,6339,343
Accumulated deficit(55,823)(57,818)(59,415)(61,910)(63,541)(67,165)(84,873)(90,203)(93,092)(91,369)(96,924)(96,036)
Total stockholders' equity373893101,364(23)12,7473,3352,6315,8497,22415,02416,492
Total liabilities and equity19,47618,50618,31817,75517,01946,44931,74419,31918,83220,22024,65625,835
Common shares outstanding (cover page) thousands of shares2,4752,7433,8093,9064,9361,0662,1494,36315,1301,7861,7862,507
  • † Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (IVF's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025†Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,248)(1,995)*(1,597)(2,245)(1,631)(3,623)*(17,404)(5,285)(2,645)2,010*(5,539)889
Stock-based compensation252*————————year only——
Depreciation and amortization21*142*227230*230*232*234170*137*136*143146*
Net cash from operating activities(1,247)*(715)*(261)(1,456)*(641)*(617)*(3,546)(1,718)*(1,777)*25*(1,917)(1,101)*
Purchases of property and equipment108*75*5055*0*79*159*8*12*——
Net cash from investing activities(2,258)*33*(24)(5)*0*393*(15)(15)*(8)*(2,707)*(210)(2)*
Proceeds from issuing common stock2,996*(23)*——0*0*8,7480*0*3,608*——
Proceeds from issuing equity—(2,600)*500——year only————7,1000*
Net cash from financing activities4,449*(142)*5271,929*169*494*3,6591,442*1,591*4,404*4,953(68)*
Net change in cash943*(823)*243468*(471)*270*99(291)*(193)*1,722*2,827(1,172)*
  • † Share count changed about 2x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
INVO Fertility3,7332,175(1,101)*2.5M3.4 quarters 10-QJun 30, 2026
LogicMark3,4963,34983*899,759— 10-QJun 30, 2026
Stimcell Energetics6.9not reported(109)21.1M0.1 quarters 10-QAug 31, 2026
Bluejay Diagnostics9,599not reported(1,499)*4.5M6.4 quarters 10-QJun 30, 2026
Interpace Biosciences2,6889,13198*27.7M— 10-QJun 30, 2026
Global Innovative Platforms24451(134)*49.8M1.8 quarters 10-QJun 30, 2026
ENDRA Life Sciences1,740not reported(928)*1.5M1.9 quarters 10-QJun 30, 2026
Vycor Medical159418(4.8)*33.4M32.8 quarters 10-QJun 30, 2026
QHSLab317847(7.8)*15.0M40.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.